May Lauren T, Sexton Patrick M, Christopoulos Arthur
Molecular Pharmacology Laboratory, Department of Pharmacology, The University of Melbourne, Parkville, 3010 Victoria, Australia.
Br J Pharmacol. 2005 Dec;146(8):1119-29. doi: 10.1038/sj.bjp.0706419.
The effect of denaturation and/or extraction of nonintegral membrane proteins by 7 M urea on the binding of the antagonist [3H]cyclopentyl-1,3-dipropylxanthine 8 dipropyl-2,3 ([3H]DPCPX), and the agonists adenosine, (-)-N6-(2-phenylisopropyl)-adenosine (R-PIA) and N6-cyclohexyladenosine (CHA), was investigated at human A1 adenosine receptors stably expressed in CHO cells. Pretreatment with urea caused a 56% reduction in membrane proteins. Compared to controls, the use of adenosine deaminase (ADA), 100 microM 5'-guanylylimidodiphosphate (Gpp(NH)p) or urea each caused equivalent increases in specific [3H]DPCPX binding. Neither the binding kinetics nor the affinity of [3H]DPCPX were significantly different in urea-pretreated compared to ADA-pretreated membranes. At 25 degrees C in ADA-pretreated membranes, the competition isotherms for R-PIA and CHA were characterized by two affinity states. Gpp(NH)p (100 microM) reduced, but did not abolish, the value of the high-affinity dissociation constant. Similar results were obtained after treatment with urea for R-PIA, whereas the high-affinity state for CHA was abolished. At 37 degrees C, urea pretreatment, but not 100 microM Gpp(NH)p, abolished high-affinity agonist competition binding. There was no significant effect of any of the treatments on the low-affinity agonist binding state. In urea-pretreated membranes, exogenously added adenosine competed according to a simple mass-action model with a pK(L) of 5.66+/-0.05 (n=3). Compared to the more common approaches of ADA treatment and/or use of guanine nucleotides, our findings suggest that urea pretreatment represents an inexpensive and useful approach for investigating the binding properties of adenosine A1 ligands (including adenosine) to the G protein-uncoupled form of the receptor.
研究了7M尿素对非整合膜蛋白的变性和/或提取作用,对稳定表达于CHO细胞中的人A1腺苷受体上拮抗剂[3H]环戊基-1,3-二丙基黄嘌呤8-二丙基-2,3([3H]DPCPX)以及激动剂腺苷、(-)-N6-(2-苯异丙基)-腺苷(R-PIA)和N6-环己基腺苷(CHA)结合的影响。用尿素预处理导致膜蛋白减少56%。与对照组相比,使用腺苷脱氨酶(ADA)、100μM 5'-鸟苷酰亚胺二磷酸(Gpp(NH)p)或尿素均使特异性[3H]DPCPX结合等量增加。与ADA预处理的膜相比,尿素预处理的膜中[3H]DPCPX的结合动力学和亲和力均无显著差异。在25℃下,ADA预处理的膜中,R-PIA和CHA的竞争等温线具有两种亲和力状态。Gpp(NH)p(100μM)降低但未消除高亲和力解离常数的值。用尿素处理R-PIA后得到类似结果,而CHA的高亲和力状态被消除。在37℃下,尿素预处理而非100μM Gpp(NH)p消除了高亲和力激动剂竞争结合。任何处理对低亲和力激动剂结合状态均无显著影响。在尿素预处理的膜中,外源添加的腺苷根据简单质量作用模型进行竞争,pK(L)为5.66±0.05(n = 3)。与更常用的ADA处理和/或使用鸟嘌呤核苷酸的方法相比,我们的研究结果表明,尿素预处理是一种用于研究腺苷A1配体(包括腺苷)与G蛋白非偶联形式受体结合特性的廉价且有用的方法。